21 C.F.R. § 1301.74 - Other security controls for non-practitioners; narcotic treatment programs and compounders for narcotic treatment programs

Cite as21 C.F.R. § 1301.74
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
82 practice notes
42 cases
  • City of S.F. v. Purdue Pharma L.P., Case No. 3:18-cv-07591-CRB
    • United States
    • United States District Courts. 9th Circuit. United States District Courts. 9th Circuit. Northern District of California
    • September 30, 2020
    ...and distributors—to "design and operate a system to disclose to the registrant suspicious orders of controlled substances." 21 C.F.R. 1301.74(b). The MDL court concluded that these regulations impose duties on manufacturers and distributors to identify, report, and refrain from shipping sus......
  • Walmart Inc. v. U.S. Dep't of Justice, CIVIL NO. 4:20-CV-817-SDJ
    • United States
    • United States District Courts. 5th Circuit. United States District Court of Eastern District Texas
    • February 4, 2021
    ...suspicious orders of controlled substances" and to notify DEA of such "suspicious orders" when discovered by the registrant. 21 C.F.R. § 1301.74(b). The regulation defines "suspicious orders" to include "orders of unusual size, orders deviating substantially from a normal pattern, and order......
  • Virtus Pharm. v. Garland, Civil Action 21-2308 (CKK)
    • United States
    • United States District Courts. United States District Court (Columbia)
    • September 22, 2021
    ...For example, registrants must “design and operate a system to disclose . . . suspicious orders of controlled substances, ” 21 C.F.R. § 1301.74(b), report instances of theft to the DEA, id. at § 1301.74(c), and maintain certain physical security conditions at their facilities, see id. at §§ ......
  • W. Boca Med. Ctr., Inc. v. Amerisourcebergen Drug Corp. (In re Nat'l Prescription Opiate Litig.), MDL 2804
    • United States
    • United States District Courts. 6th Circuit. United States District Court of Northern District of Ohio
    • April 3, 2020
    ...("SOMS"), as well as by failing to actually disclose such suspicious orders, as required of ‘registrants’ by the federal CSA, 21 C.F.R. § 1301.74(b), which is incorporated into Florida law by the FLDCA [Drug and Cosmetic Act], including Fla. Stat. § 499.0121.Doc. #: 385 at ¶902. West Boca f......
  • Request a trial to view additional results
9 firm's commentaries
1 provisions
  • P.A. 19-0191, HB 7159 – AN ACT ADDRESSING OPIOID USE
    • United States
    • Connecticut Session Laws
    • January 1, 2019
    ...Division a copy of any suspicious [activity reporting] orders submitted to the federal Drug Enforcement Administration pursuant to 21 CFR 1301.74. (2) Each registered manufacturer or wholesaler of drugs that, based on concerns of potential diversion, ceases or declines distribution of any s......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT